Dr. Yunching (Becky) Chen received her Ph.D. in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill in 2010, under the mentorship of Dr. Leaf Huang. She then completed her postdoctoral training at the Department of Radiation Oncology at Harvard Medical School and Massachusetts General Hospital, where she collaborated with Drs. Rakesh Jain and Dan Duda. In 2013, Dr. Chen joined National Tsing Hua University as a tenure-track Assistant Professor and was promoted to Full Professor in 2020, where she also served as Chair of the Institute of Biomedical Engineering. She is currently a Research Fellow at the Institute of Biological Chemistry, Academia Sinica. Dr. Chen's research centers on the development of innovative drug delivery systems for the targeted administration of nucleic acids, proteins, chemotherapeutics, and immunotherapeutic agents. Her work addresses pressing challenges in the treatment of cancer and inflammatory diseases, including renal fibrosis and liver cirrhosis. Her research has been widely published in high-impact journals, including Nature Reviews Bioengineering, Advanced Drug Delivery Reviews, Nature Nanotechnology, Nature Protocols, Advanced Materials, Advanced Functional Materials, Advanced Science, Science Advances, ACS Nano, Gut, Hepatology, and the Journal of Controlled Release. In addition to her academic achievements, Dr. Chen holds several prominent leadership roles in the scientific community. She is Chair of the International Chapter Committee of the Controlled Release Society (CRS), Deputy Editor-in-Chief of the Journal of Controlled Release, Guest Editor of Advanced Drug Delivery Reviews, and serves on the editorial board of Drug Delivery and Translational Research and ACS Nano Medicine.

The Immunoengineering and Drug Delivery Laboratory focuses on the rational design of advanced drug delivery systems to modulate immune responses in cancer and inflammatory diseases. Our research integrates biomaterials science, nanotechnology, and immunology to develop targeted platforms that precisely control the spatial and temporal delivery of therapeutic agents. By engineering interactions between delivery systems and the tumor microenvironment, including immune and stromal components, we aim to overcome therapeutic resistance and improve treatment efficacy. Through mechanistic studies and translationally oriented models, our laboratory seeks to bridge fundamental immunoengineering principles with clinically relevant therapeutic strategies.